MERCK KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 167.2 EUR | -0.89% |
|
+7.52% | +16.03% |
| 05-16 | MERCK KGAA : DZ Bank gives a Buy rating | ZD |
| 05-16 | MERCK KGAA : Gets a Buy rating from Barclays | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.26B 23.11B 31.45B | Sales 2025 * | 22.49B 24.44B 33.27B | Capitalization | 72.69B 79B 108B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.96B 3.21B 4.38B | Net income 2025 * | 3.46B 3.76B 5.11B | EV / Sales 2024 * | 3.8 x |
| Net Debt 2024 * | 8.17B 8.88B 12.09B | Net Debt 2025 * | 5.07B 5.51B 7.5B | EV / Sales 2025 * | 3.46 x |
| P/E ratio 2024 * |
24.3
x | P/E ratio 2025 * |
20.6
x | Employees | 62,345 |
| Yield 2024 * |
1.36% | Yield 2025 * |
1.45% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
More news
| 1 day | -0.89% | ||
| 1 week | +7.52% | ||
| Current month | +12.25% | ||
| 1 month | +13.59% | ||
| 3 months | +7.39% | ||
| 6 months | +6.53% | ||
| Current year | +16.03% |
1 week
154.20
169.05
1 month
144.40169.05
Current year
140.50169.05
1 year
134.30172.40
3 years
134.30231.50
5 years
76.22231.50
10 years
61.05231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 20-07-12 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 14-07-31 |
| Director of Finance/CFO | 53 | 19-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 14-05-08 | |
Christian Raabe
BRD | Director/Board Member | - | - |
| Chairman | 67 | 19-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 2.01% | 0 M€ | 0.00% | - | |
| 1.80% | 962 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 167.2 | -0.89% | 286,898 |
| 24-05-16 | 168.7 | +1.72% | 498,812 |
| 24-05-15 | 165.8 | +4.77% | 741,893 |
| 24-05-14 | 158.3 | +2.46% | 298,795 |
| 24-05-13 | 154.5 | -0.64% | 235,637 |
Delayed Quote Xetra, May 17, 2024 at 11:35 am
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
167.2
EUR
Average target price
180.8
EUR
Spread / Average Target
+8.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.03% | 79.73B | |
| +10.23% | 9.11B | |
| -10.76% | 5.21B | |
| +51.58% | 4.83B | |
| +12.50% | 4.09B | |
| -20.70% | 2.35B | |
| +12.83% | 2.32B | |
| +19.51% | 2.27B | |
| -29.65% | 2.19B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock
